RITONAVIR by Cipla is fixed-dose combination of hiv-1 antiviral drugs lopinavir [see microbiology ()] and ritonavir. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection in adults, older). First approved in 2022.
Drug data last refreshed 6h ago
fixed-dose combination of HIV-1 antiviral drugs lopinavir [see Microbiology ()] and ritonavir. As co-formulated in lopinavir and ritonavir tablets, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
Worked on RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People